Results 41 to 50 of about 51,405 (260)

ω3 Polyunsaturated Fatty Acids as Immunomodulators in Colorectal Cancer: New Potential Role in Adjuvant Therapies [PDF]

, 2016
Diet composition may affect the onset and progression of chronic degenerative diseases, including cancer, whose pathogenesis relies on inflammatory processes.
Anna Maria Mileo, Roberta Masella, Sandra Gessani, Stefania Miccadei   +3 more
core   +8 more sources

Are the true impacts of adverse events considered in economic models of antineoplastic drugs? a systematic review [PDF]

, 2013
Background: Antineoplastic drugs for cancer are often associated with adverse events, which influence patients' physical health, quality of life and survival. However, the modelling of adverse events in cost-effectiveness analyses of antineoplastic drugs
Haas, M, Pearce, A, Viney, R
core   +1 more source

Changes in Body Composition in Children and Young People Undergoing Treatment for Acute Lymphoblastic Leukemia: A Systematic Review and Meta‐Analysis

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Ongoing evidence indicates increased risk of sarcopenic obesity among children and young people (CYP) with acute lymphoblastic leukemia (ALL), often beginning early in treatment, persisting into survivorship. This review evaluates current literature on body composition in CYP with ALL during and after treatment.
Lina A. Zahed, Raquel Revuelta Iniesta, Mary Fewtrell, Julie Lanigan, Breeana Gardiner, Graeme O'Connor   +5 more
wiley   +1 more source

Compliance with a protocol for acute lymphoblastic leukemia in childhood

Revista Brasileira de Hematologia e Hemoterapia, 2011
BACKGROUND: Remission rates achieved after the initial treatment of acute lymphoblastic leukemia may be similar in both developed and developing countries, but relapse rates are much higher in the latter.
Benigna Maria de Oliveira, Maria Thereza Macedo Valadares, Marcilene Rezende Silva, Marcos Borato Viana   +3 more
doaj   +1 more source

Organoids in pediatric cancer research

FEBS Letters, EarlyView.
Organoid technology has revolutionized cancer research, yet its application in pediatric oncology remains limited. Recent advances have enabled the development of pediatric tumor organoids, offering new insights into disease biology, treatment response, and interactions with the tumor microenvironment.
Carla Ríos Arceo, Jarno Drost
wiley   +1 more source

Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo [PDF]

, 2018
Lenvatinib is an oral, multitargeted tyrosine kinase inhibitor (TKI) of VEGFR1-VEGFR3, FGFR1-FGFR4, PDGFRα, RET and v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog (KIT) signaling networks involved in tumor angiogenesis.
Antonelli, Alessandro, Baldini, Enke, Bocci, Guido, Di Desidero, Teresa, Elia, Giusy, Fallahi, Poupak, Ferrari, Silvia Martina, Materazzi, Gabriele, Miccoli, Paolo, Motta, Concettina La, Orlandi, Paola, Paparo, Sabrina Rosaria, Patrizio, Armando, Piaggi, Simona, Ragusa, Francesca, Ruffilli, Ilaria, Ulisse, Salvatore   +16 more
core   +2 more sources

Glycosylated LGALS3BP is highly secreted by bladder cancer cells and represents a novel urinary disease biomarker

Molecular Oncology, EarlyView.
Urinary LGALS3BP is elevated in bladder cancer patients compared to healthy controls as detected by the 1959 antibody–based ELISA. The antibody shows enhanced reactivity to the high‐mannose glycosylated variant secreted by cancer cells treated with kifunensine (KIF).
Asia Pece, Giulio Lovato, Ilaria Cela, Arianna Mercatelli, Benedetta Ferro, Jussi Nikkola, Sara Pagotto, Tommaso Grottola, Vincenzo De Laurenzi, Rossella Cicchetti, Antonio Marchetti, Luigi Schips, Rossano Lattanzio, Stefano Iacobelli, Emily Capone, Peter Black, Mads Daugaard, Michele Marchioni, Gianluca Sala   +18 more
wiley   +1 more source

Reproductive adverse events in patients with non‐Hodgkin lymphoma treated with chemotherapeutic regimens including cyclophosphamide, doxorubicin, vincristine, prednisone or CHOP with rituximab: A systematic review and meta‐analysis

Pediatric Discovery
The regimen of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP with rituximab (R‐CHOP) is the first‐line treatment for non‐Hodgkin lymphoma (NHL).
Rong Han, Jie Zhao, Chengjun Yu, Ling Wang, Long Chen, Yang Hu, Shengde Wu   +6 more
doaj   +1 more source

Multi-Institutional experience with FOLFIRINOX in pancreatic adenocarcinoma [PDF]

, 2012
Combination chemotherapy with FOLFIRINOX (oxaliplatin, irinotecan, fluorouracil, and leucovorin) was shown to be effective in a large phase III trial.
Gao, Feng, Linehan, David, Lockhart, A Craig, Lubner, Sam, McWilliams, Robert, Menias, Christine, Peddi, Parvin F, Picus, Joel, Sorscher, Steven M, Suresh, Rama, Tan, Benjamin R, Wang, Jian, Wang-Gilliam, Andrea   +12 more
core   +3 more sources

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source